Race Oncology Limited (RAONF)
USD 1.22
(0.0%)
USD 1.22
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -17.18 Million AUD | -795.08% |
| 2023 | -1.27 Million AUD | 69.32% |
| 2022 | -4.16 Million AUD | 40.44% |
| 2021 | -6.99 Million AUD | -487.33% |
| 2020 | -1.19 Million AUD | -71.75% |
| 2019 | -693.82 Thousand AUD | 74.69% |
| 2018 | -2.74 Million AUD | -110.61% |
| 2017 | -1.3 Million AUD | 59.76% |
| 2016 | -3.23 Million AUD | -15094.57% |
| 2015 | -21.28 Thousand AUD | 55.91% |
| 2014 | -48.27 Thousand AUD | 53.66% |
| 2013 | -104.19 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -13.71 Million USD | 0.0% |
| 2024 Q4 | -17.18 Million AUD | 0.0% |
| 2024 Q1 | -13.71 Million AUD | -972.39% |
| 2023 Q2 | -26.37 Million USD | 0.0% |
| 2023 Q4 | -1.27 Million AUD | 94.06% |
| 2023 Q3 | -21.52 Million AUD | 18.4% |
| 2023 Q1 | -26.37 Million AUD | -532.72% |
| 2023 FY | -1.27 Million AUD | 69.32% |
| 2022 Q1 | -37.1 Million AUD | -430.12% |
| 2022 FY | -4.16 Million AUD | 40.44% |
| 2022 Q4 | -4.16 Million AUD | 87.57% |
| 2022 Q3 | -33.54 Million AUD | 9.6% |
| 2022 Q2 | -37.1 Million USD | 0.0% |
| 2021 Q4 | -6.99 Million AUD | 24.92% |
| 2021 Q3 | -9.32 Million AUD | -67.16% |
| 2021 Q1 | -5.57 Million AUD | -368.02% |
| 2021 Q2 | -5.57 Million USD | 0.0% |
| 2021 FY | -6.99 Million AUD | -487.33% |
| 2020 Q2 | -1.54 Million USD | 0.0% |
| 2020 Q3 | -1.73 Million AUD | -11.77% |
| 2020 Q4 | -1.19 Million AUD | 31.15% |
| 2020 FY | -1.19 Million AUD | -71.75% |
| 2020 Q1 | -1.54 Million AUD | -123.19% |
| 2019 Q3 | -988.71 Thousand AUD | 52.44% |
| 2019 Q1 | -2.07 Million AUD | 43.97% |
| 2019 FY | -693.82 Thousand AUD | 74.69% |
| 2019 Q4 | -693.82 Thousand AUD | 29.83% |
| 2019 Q2 | -2.07 Million AUD | 0.0% |
| 2018 Q1 | -1.63 Million AUD | 3.67% |
| 2018 FY | -2.74 Million AUD | -110.61% |
| 2018 Q4 | -3.7 Million AUD | 0.0% |
| 2018 Q3 | -3.7 Million AUD | -126.98% |
| 2018 Q2 | -1.63 Million AUD | 0.0% |
| 2017 Q3 | -1.69 Million AUD | 44.27% |
| 2017 FY | -1.3 Million AUD | 59.76% |
| 2017 Q4 | -1.69 Million AUD | 0.0% |
| 2017 Q2 | -3.04 Million AUD | 0.0% |
| 2017 Q1 | -3.04 Million AUD | 29.9% |
| 2016 Q2 | -827.00 AUD | 0.0% |
| 2016 Q1 | -827.00 AUD | 96.12% |
| 2016 Q4 | -4.34 Million AUD | 0.0% |
| 2016 Q3 | -4.34 Million AUD | -525183.68% |
| 2016 FY | -3.23 Million AUD | -15094.57% |
| 2015 Q1 | 48.27 Thousand AUD | 0.0% |
| 2015 Q4 | -21.28 Thousand AUD | 0.0% |
| 2015 Q3 | -21.28 Thousand AUD | 0.0% |
| 2015 FY | -21.28 Thousand AUD | 55.91% |
| 2014 FY | -48.27 Thousand AUD | 53.66% |
| 2013 FY | -104.19 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 209.045% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 517.405% |
| SQZ Biotechnologies Company | -36.23 Million USD | 52.567% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 140.167% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -172.643% |
| Mesoblast Limited | 55.85 Million USD | 130.772% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1953.87% |
| Genus plc | 190.6 Million USD | 109.018% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 868.789% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 1516.014% |
| Marizyme, Inc. | 18.56 Million USD | 192.567% |
| ContraFect Corporation | -6.02 Million USD | -185.244% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 2627.769% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 12866.603% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1587.658% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 866.594% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 412.416% |
| MultiCell Technologies, Inc. | 90.04 USD | 19090312.128% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -2241.872% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 232.773% |
| EV Biologics, Inc. | 1.36 Million USD | 1356.52% |
| Q BioMed Inc. | 4.06 Million USD | 523.369% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 156.257% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 2861.861% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1805.721% |
| Biomind Labs Inc. | 711.4 Thousand USD | 2516.19% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 115.654% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 234.219% |
| Skye Bioscience, Inc. | -5.72 Million USD | -200.431% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 2098.141% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 12394.946% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 404.315% |
| IMV Inc. | 7.67 Million USD | 324.089% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 86619.49% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 880.607% |
| GB Sciences, Inc. | 1.74 Million USD | 1083.727% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -9252.53% |
| HST Global, Inc. | 96.79 Thousand USD | 17858.337% |
| CSL Limited | 10.52 Billion USD | 100.163% |
| Halberd Corporation | 144.72 Thousand USD | 11977.217% |
| Enzolytics Inc. | 981.65 Thousand USD | 1851.003% |
| Resverlogix Corp. | 6.45 Million USD | 366.452% |
| Affymax, Inc. | -5.59 Million USD | -207.108% |
| SYBLEU INC | 473.71 Thousand USD | 3728.524% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -2453.723% |
| argenx SE | -2.02 Billion USD | 99.153% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 139.575% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 63.437% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 734.598% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -94.446% |
| AVAX Technologies, Inc. | -5.9 Million USD | -191.178% |
| Zenith Capital Corp. | 10.06 Thousand USD | 170895.181% |
| Genscript Biotech Corporation | -1.06 Billion USD | 98.38% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 8675.89% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 820.393% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 10548.563% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 128.39% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 959.703% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -568.818% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 4878.524% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 184.774% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -93735.719% |
| BioStem Technologies, Inc. | 4.47 Million USD | 484.365% |
| ONE Bio Corp. | 9.04 Million USD | 290.141% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 8640.862% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -1312024.198% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 8435.31% |
| Agentix Corp. | 37.63 Thousand USD | 45777.306% |
| LadRx Corporation | -2.03 Million USD | -744.051% |
| Cell Source, Inc. | 9.23 Million USD | 286.188% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -84125.926% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2806.19% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 2806.19% |
| NovAccess Global Inc. | 2.17 Million USD | 889.034% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 343.09% |
| Itoco Inc. | 228.3 Thousand USD | 7628.888% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 12739.866% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 446.759% |
| Kadimastem Ltd | -253.1 Thousand USD | -6691.265% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 4377.434% |
| CytoDyn Inc. | 20.26 Million USD | 184.833% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -2656596.6% |
| Mobile Lads Corp. | 484.23 Thousand USD | 3649.709% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -185357.45% |
| Qrons Inc. | 351.42 Thousand USD | 4991.152% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 323.058% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -6785.998% |
| Rebus Holdings, Inc. | 305 Thousand USD | 5735.681% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 485.657% |
| International Stem Cell Corporation | 2.59 Million USD | 763.661% |
| Bioxytran, Inc. | 1.89 Million USD | 1005.192% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 27640.46% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 888.153% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 600.548% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 300.968% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 2324.783% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -1275.106% |
| Neutra Corp. | 52.18 Thousand USD | 33036.99% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -590.592% |
| PureTech Health plc | -167.19 Million USD | 89.719% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -6918.483% |
| IXICO plc | -4.44 Million USD | -286.736% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 230.031% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 131.337% |
| CSL Limited | 10.52 Billion USD | 100.163% |
| Cellectis S.A. | -43.81 Million USD | 60.773% |